Zimmer Biomet Holdings, Inc. (ZBH)

Market Cap	19.54B -2.3%
Revenue (ttm)	8.23B +7.2%
Net Income	705.10M -22.0%
EPS	3.55 -19.9%
Shares Out	195.65M
PE Ratio	28.13
Forward PE	11.88
Dividend	$0.96 (0.96%)
Ex-Dividend Date	Mar 31, 2026

Volume	1,452,017
Open	100.00
Previous Close	99.87
Day's Range	98.48 - 100.53
52-Week Range	84.59 - 114.44
Beta	0.61
Analysts	Hold
Price Target	105.17 (+5.33%)
Earnings Date	Feb 10, 2026

About ZBH

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open hear...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1927
• Employees: 17,000
• Stock Exchange: NYSE
• Ticker Symbol: ZBH
• Website: https://www.zimmerbiomet.com

Financial Performance

In 2025, Zimmer Biomet Holdings's revenue was $8.23 billion, an increase of 7.20% compared to the previous year's $7.68 billion. Earnings were $705.10 million, a decrease of -21.98%.

Analyst Summary

According to 19 analysts, the average rating for ZBH stock is "Hold." The 12-month stock price target is $105.17, which is an increase of 5.33% from the latest price.

Price Target

$105.17

(5.33% upside)

Analyst Consensus: Hold